EYPT
EyePoint Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -2.9% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 78 | +2 | 47.62M | $680.75M | +5 | −3 |
| Q1 2026 | 79 | +9 | 48.20M | $619.80M | +12 | −3 |
| Q4 2025 | 69 | +1 | 44.57M | $814.29M | +2 | −1 |
| Q3 2025 | 14 | -1 | 22.98M | $327.28M | — | −1 |
| Q2 2025 | 12 | 0 | 22.66M | $213.25M | — | — |
| Q1 2025 | 9 | -1 | 13.73M | $74.43M | — | −1 |
| Q4 2024 | 10 | 0 | 15.37M | $114.47M | +1 | −1 |
| Q3 2024 | 9 | -2 | 10.25M | $81.94M | — | −2 |
| Q2 2024 | 11 | — | 10.63M | $92.49M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners ✦ | 6.80M | +9.7% | $63.99M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 2 | BlackRock ✦ (passive) | 5.36M | — | $50.44M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 3 | The Vanguard Group ✦ (passive) | 3.80M | — | $35.78M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 4 | Citadel Advisors ✦ | 2.34M | +2.5% | $22.06M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 5 | Geode Capital Management ✦ (passive) | 1.59M | -0.1% | $14.98M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 6 | State Street Global Advisors ✦ (passive) | 1.52M | -4.9% | $14.26M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 7 | Fidelity (FMR) ✦ | 446.31K | — | $4.20M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 8 | Two Sigma Investments ✦ | 376.78K | +16.3% | $3.55M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 9 | Wellington Management ✦ | 265.11K | +13.7% | $2.49M | 0.0% | ▲ Add | 5 | SEC ↗ ×3 |
| 10 | T. Rowe Price ✦ | 83.71K | -93.8% | $788,000 | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 11 | Millennium Management ✦ | 38.15K | +23.9% | $358,982 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 12 | Renaissance Technologies ✦ | 37.00K | -68.5% | $348,170 | 0.0% | ▼ Trim | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 40.00K shares, $515 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Director · 10.60K sh @ 4.93 · $52,258
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology